WHO
Approval, ownership, market structure, and placement on WHO EML for 100 new cancer NMEs on NCI alpha list
KEI research associate Paul Miano has written the following paper: Cancer: Approval, ownership, market structure, and placement on WHO Model Essential Medicines List, for 100 new molecular entities (NMEs) on the NCI alpha list of cancer drugs and vaccines. KEI Research Note 2011:1,
A full copy of the paper is available in PDF format here.
The following is from the introduction (sans footnotes, which are in the PDF version):
Introduction and Summary
Working Document Proposed by Barbados and Bolivia
https://www.keionline.org/misc-docs/b_b_igwg/working_document_barbados_bolivia.pdf April 2008 According to resolution WHA60.30 on Public Health, Innovation and Intellectual Property, the Director-General of the WHO is asked: (4) to encourage the development of proposals for health-needs driven research and development for discussion at the Intergovernmental Working… Continue Reading
2007 KEI Letter to WHO on the Essential Medicines List
March 2, 2007 Secretary of the Expert Committee on the Selection and Use of Essential Medicines (2007)Department of Medicines Policy and Standards (PSM)Health Technology & PharmaceuticalsWorld Health OrganizationCH-1211 Geneva 27Switzerland Via e-mail: emisecretariat@who.int RE: Request for changes in the WHO Model… Continue Reading